Andecaliximab Anti-MMP9 Reference Antibody (andecaliximab)|cas:1518996-49-0|西域试剂

Andecaliximab Anti-MMP9 Reference Antibody (andecaliximab)

产品编号：Bellancom-P99351| CAS NO：1518996-49-0

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-P99351	￥3000.00	杭州北京（现货）
Bellancom-P99351	￥7800.00	杭州北京（现货）
Bellancom-P99351	￥12500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Andecaliximab Anti-MMP9 Reference Antibody (andecaliximab)

产品介绍

Andecaliximab 是一种靶向基质金属蛋白酶 9 (MMP9) 的重组 IgG4 单克隆抗体。Andecaliximab 在特发性肺纤维化小鼠模型中显示出抗纤维化疗效。Andecaliximab 可用于胃腺癌和特发性肺纤维化 (IPF) 的研究。

生物活性

Andecaliximab is a recombinant chimeric IgG4 monoclonal antibody (mAb) targets matrix metalloproteinase 9 (MMP9). Andecaliximab shows the antifibrotic efficacy in idiopathic pulmonary fibrosis mouse models. Andecaliximab can be used for the research of gastric adenocarcinoma and idiopathic pulmonary fibrosis (IPF).

体外研究

Andecaliximab 增加血清中 IL-7 的水平。
Andecaliximab (50 μg/mL；24 h)减少 ABC 类细胞系的 SMAD2 磷酸化 (pSMAD2)。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Andecaliximab 改善肿瘤浸润 T 细胞内 T 细胞受体 (TCR) 的多样性。
Andecaliximab (20 mg/kg；腹腔注射，单次) 在特发性肺纤维化的人源 NSG 小鼠模型中显示出抗纤维化功效。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Humanized nonobese diabetic, SCID, IL-2 receptor g (NSG) mouse model of IPF
Dosage:	20 mg/kg
Administration:	Intraperitoneal injection; 20 mg/kg, once a week for once
Result:	Decreased SMAD2 phosphorylation and increased surfactant protein C. Reduced MMP9⁺ cells, including MMP9⁺, CCR10⁺ and MMP9⁺CD45^- and EpCAM⁺CCR10⁺ subpopulations.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Humanized nonobese diabetic, SCID, IL-2 receptor g (NSG) mouse model of IPF
Dosage:	20 mg/kg
Administration:	Intraperitoneal injection; 20 mg/kg, once a week for once
Result:	Decreased SMAD2 phosphorylation and increased surfactant protein C. Reduced MMP9⁺ cells, including MMP9⁺, CCR10⁺ and MMP9⁺CD45^- and EpCAM⁺CCR10⁺ subpopulations.